Hypoxia-inducible regulation of a prodrug-activating enzyme for tumor-specific gene therapy

Neoplasia

Volumn 4, Issue 1, 2002, Pages 40-48

  Shibata, Toru ^b   Giaccia, Amato J ^a   Martin Brown, J ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

CB 1954; Gene therapy; Nitroreductase; Tumor hypoxia; Vascular endothelial growth factor

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; NITROREDUCTASE; VASCULOTROPIN;

ANIMAL EXPERIMENT; ARTICLE; CANCER; CANCER INHIBITION; CANCER THERAPY; CONTROLLED STUDY; CYTOTOXICITY; DNA VECTOR; DRUG ACTIVATION; DRUG SENSITIVITY; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HYPOXIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; TUMOR XENOGRAFT;

EID: 0036145795     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj/neo/7900189     Document Type: Article

References (50)

1. The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy
2. 2 predicts survival in advanced cancer of the uterine cervix
3. Tumour hypoxia and vascular density as predictors of metastasis in squamous cell carcinoma of the uterine cervix
4. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck
5. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck
6. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma
7. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
8. The regulated expression of erythropoietin by two human hepatoma cell lines
9. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation
10. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
11. Hypoxia-inducible nuclear factors bind to an enhancer element located 3′ to the human erythropoietin gene
12. A 24-base pair sequence 3′ to the human erythropoietin gene contains a hypoxia-responsive transcriptional enhancer
13. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1
14. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1
15. Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin
16. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth
17. In vitro and in vivo targeting of gene expression to melanoma cells
18. Prostate tissue specificity of the prostate-specific antigen promoter isolated from a patient with prostate cancer
19. Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: An innovative approach for cancer therapy
20. The molecular response of mammalian cells to hypoxia and the potential for exploitation in cancer therapy
21. Targeting gene expression to hypoxic tumor cells
22. Enhancement of gene expression under hypoxic conditions using fragments of the human vascular endothelial growth factor and the erythropoietin genes
23. Killing of brain tumor cells by hypoxia-responsive element-mediated expression of BAX
24. Development of a hypoxia-responsive vector for tumor-specific gene therapy
25. 2,4-Dinitro-5-ethyleneiminobenzamide (CB 1954): A potent and selective inhibitor of the growth of the Walker carcinoma 256
26. The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2)
27. Molecular basis of the catalytic differences among DT-diaphorase of human, rat, and mouse
28. The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954): I. Purification and properties of a nitroreductase enzyme from Escherichia coli - A potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT)
29. The bioactivation of 5-(azirdin-1-yl)-2,4-dinitrobenzamide (CB1954): II. A comparison of an Escherichia coli nitroreductase and Walker DT-diaphorase
30. Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954
31. Selective cell ablation in transgenic mice expression E. coil nitroreductase
32. The expression of bacterial nitroreductase in transgenic mice results in specific cell killing by the prodrug CB1954
33. Virus-directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954
34. The choice of prodrugs for gene-directed enzyme prodrug therapy of cancer
35. SR 4233 (tirapazamine): A new anticancer drug exploiting hypoxia in solid tumours
36. Oxygen tension measurements of tumors growing in mice
37. Modulation of firefly luciferase stability and impact on studies of gene regulation
38. 2 tension measurements
39. Hypoxic regions exist in human prostate carcinoma
40. Oxygenation of squamous cell carcinoma of the head and neck: Comparison of primary tumors, neck node metastases, and normal tissue
41. 2 tension
42. Gene-directed enzyme prodrug therapy: Quantitative bystander cytotoxicity and DNA damage induced by CB1954 in cells expressing bacterial nitroreductase
43. Reduction of tumor blood flow by flavone acetic acid: A possible component of therapy
44. Role of tumor necrosis factor in flavone acetic acid-induced tumor vasculature shutdown
45. Antivascular approaches to solid tumour therapy: Evaluation of tubulin binding agents
46. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression
47. Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells
48. Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression
49. Overexpression of hypoxia-inducible factor 1 alpha in common human cancers and their metastases
50. The macrophage - A novel system to deliver gene therapy to pathological hypoxia